专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5965536A Methods of inhibiting CXC intercrine molecules 失效
标题翻译：抑制CXC分泌分子的方法
公开(公告)号：US5965536A
公开(公告)日：1999-10-12
申请号：US666564
申请日：1996-06-14
申请人： Allen Barry Cohen, deceased , Edmund J. Miller , Shinichiro Hayashi , Anna K. Kurdowska , Ronald R. Tuttle
发明人： Allen Barry Cohen, deceased , Edmund J. Miller , Shinichiro Hayashi , Anna K. Kurdowska , Ronald R. Tuttle
IPC分类号： A61K38/00 , C07K7/06 , C07K14/54 , A61K38/02 , C07K5/00 , C07K7/00
CPC分类号： C07K7/06 , C07K14/54 , C07K14/5421 , A61K38/00
摘要： Disclosed are methods for inhibiting and modulating the actions of CXC intercrine molecules. The antileukinate peptides described inhibit IL-8, GRO and MIP2.beta. binding to neutrophils and neutrophil activation. The peptides are particularly advantageous as they inhibit IL-8-induced enzyme release at a 25 fold lower concentration than is required to inhibit chemotaxis, which makes them ideal for treating various inflammatory diseases and disorders including, amongst others, Adult Respiratory Distress Syndrome (ARDS), cystic fibrosis and chronic bronchitis.
摘要翻译： PCT No.PCT / US93 / 12245 Sec。 371日期1996年6月14日第 102（e）日期1996年6月14日PCT提交1993年12月15日PCT公布。出版物WO95 / 16702 日期：1995年6月22日被公开是用于抑制和调节CXC胞间分子作用的方法。所描述的抗白细胞介素肽抑制IL-8，GRO和MIP2β与嗜中性粒细胞和嗜中性粒细胞活化的结合。这些肽是特别有利的，因为它们以比抑制趋化性所需的浓度低25倍抑制IL-8诱导的酶释放，这使得它们是治疗各种炎性疾病和病症的理想选择，包括成人呼吸窘迫综合征（ARDS）），囊性纤维化和慢性支气管炎。

2. 发明授权

US06355619B1 Peptide tumor cell growth inhibitors 失效
标题翻译：肽肿瘤细胞生长抑制剂
公开(公告)号：US06355619B1
公开(公告)日：2002-03-12
申请号：US09650438
申请日：2000-08-29
申请人： Edmund J. Miller , Shinichiro Hayashi
发明人： Edmund J. Miller , Shinichiro Hayashi
IPC分类号： A61K3800
CPC分类号： C07K7/06 , A61K38/08 , C07K14/54 , C07K14/5421
摘要： Disclosed are peptide-based compositions and methods for inhibiting and modulating the actions of CXC intercrine molecules. The antileukinate peptides described inhibit IL-8, GRO and MIP2&bgr; binding to neutrophils and neutrophil activation. The peptides are particularly advantageous as they inhibit IL-8-induced enzyme release at a 25 fold lower concentration than is required to inhibit chemotaxis, which makes them ideal for treating various inflammatory diseases and disorders including, amongst others, Adult Respiratory Distress Syndrome (ARDS), cystic fibrosis and chronic bronchitis. The invention further includes methods for inhibiting tumor cell growth by employing selected members of the disclosed group of peptides to inhibit a-chemokine binding to the tumor cell.
摘要翻译：本发明公开了基于肽的组合物和用于抑制和调节CXC胞间分子作用的方法。所述的抗白细胞介素肽抑制IL-8，GRO和MIP2β结合嗜中性粒细胞和嗜中性粒细胞活化。这些肽是特别有利的，因为它们以比抑制趋化性所需的浓度低25倍抑制IL-8诱导的酶释放，这使得它们是治疗各种炎性疾病和病症的理想选择，包括成人呼吸窘迫综合征（ARDS）），囊性纤维化和慢性支气管炎。本发明还包括通过使用所公开的肽组的选定成员来抑制趋化因子与肿瘤细胞的结合来抑制肿瘤细胞生长的方法。

3. 发明授权

US6110889A Peptide tumor cell growth inhibitors 失效
标题翻译：肽肿瘤细胞生长抑制剂
公开(公告)号：US6110889A
公开(公告)日：2000-08-29
申请号：US865472
申请日：1997-05-29
申请人： Edmund J. Miller , Shinichiro Hayashi
发明人： Edmund J. Miller , Shinichiro Hayashi
IPC分类号： A61K38/00 , A61K38/08 , A61P35/00 , C07K7/06 , C07K14/54
CPC分类号： C07K7/06 , A61K38/08 , C07K14/54 , C07K14/5421
摘要： Disclosed are peptide-based compositions and methods for inhibiting and modulating the actions of CXC intercrine molecules. The antileukinate peptides described inhibit IL-8, GRO and MIP2.beta. binding to neutrophils and neutrophil activation. The peptides are particularly advantageous as they inhibit IL-8-induced enzyme release at a 25 fold lower concentration than is required to inhibit chemotaxis, which makes them ideal for treating various inflammatory diseases and disorders including, amongst others, Adult Respiratory Distress Syndrome (ARDS), cystic fibrosis and chronic bronchitis. The invention further includes methods for inhibiting tumor cell growth by employing selected members of the disclosed group of peptides to inhibit .alpha.-chemokine binding to the tumor cell.
摘要翻译：本发明公开了基于肽的组合物和用于抑制和调节CXC胞间分子作用的方法。所描述的抗白细胞介素肽抑制IL-8，GRO和MIP2β与嗜中性粒细胞和嗜中性粒细胞活化的结合。这些肽是特别有利的，因为它们以比抑制趋化性所需的浓度低25倍抑制IL-8诱导的酶释放，这使得它们是治疗各种炎性疾病和病症的理想选择，包括成人呼吸窘迫综合征（ARDS）），囊性纤维化和慢性支气管炎。本发明还包括通过使用所公开的肽组的选定成员来抑制α-细胞因子与肿瘤细胞的结合来抑制肿瘤细胞生长的方法。

4. 发明授权

US5079228A Peptide inhibitors of neutrophil activating factor induced chemotaxis 失效
标题翻译：中性粒细胞激活因子诱导趋化性肽抑制剂
公开(公告)号：US5079228A
公开(公告)日：1992-01-07
申请号：US475658
申请日：1990-02-05
申请人： Allen B. Cohen , Edmund J. Miller , Shigeki Nagao , Ferdicia K. Carr
发明人： Allen B. Cohen , Edmund J. Miller , Shigeki Nagao , Ferdicia K. Carr
IPC分类号： A61K38/00 , C07K14/54
CPC分类号： C07K14/5421 , A61K38/00
摘要： The present invention describes a method of preventing neutrophil chemotaxis, either in vitro or at a biological site using peptides whose amino acid sequence is derived at least in part from the sequence of native neutrophil activating factor (NAF). The peptides do not have measurable chemotactic activity against human neutrophils, but they are antagonistic to native NAF. The method of preventing neutrophil chemotaxis is practiced by adding sufficient amounts of the claimed peptides to neutrophils in a biological fluid or appropriate medium to inhibit neutrophil chemotaxis. The claimed peptides may have therapeutic value in patients with Adult Respiratory Distress Syndrome (ARDS) or with other inflammatory lesions known or found to be caused by NAF.
摘要翻译：本发明描述了使用其氨基酸序列至少部分地根据天然嗜中性粒细胞激活因子（NAF）的序列衍生的肽，在体外或在生物部位中预防嗜中性粒细胞趋化性的方法。肽对人嗜中性粒细胞没有可测量的趋化活性，但它们与天然NAF有拮抗作用。通过向生物流体或适当培养基中的嗜中性粒细胞加入足量的所要求的肽来抑制嗜中性粒细胞趋化性，来实施防止嗜中性粒细胞趋化性的方法。所要求保护的肽可以在患有成人呼吸窘迫综合征（ARDS）或已知或被发现由NAF引起的其它炎性损害的患者中具有治疗价值。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式